Tag: Boehringer Ingelheim
Boehringer Ingelheim acquires pet therapeutics company
Boehringer Ingelheim has bought out Saiba Animal Health AG, adding an innovative technology platform to its pet therapeutics R&D portfolio. The companies believe the...
Boehringer Ingelheim unveils new R&D laboratory
Animal health company Boehringer Ingelheim has opened its new R&D laboratory in St. Joseph, Missouri, US. This state-of-the-art facility will pioneer the development of...
Boehringer Ingelheim wins best new product award for Senvelgo
Senvelgo®, a recent innovation from Boehringer Ingelheim that makes treating diabetic cats simple, safe, and highly convenient, won the 2023 Animal Health Best New...
Boehringer Ingelheim announces appointments to Board of Managing Directors
Boehringer Ingelheim announced the appointment of Paola Casarosa and Shashank Deshpande to replace Michel Pairet, responsible for the Innovation Unit, and Jean Scheftsik de...
Boehringer Ingelheim launches Fencovis, a new vaccine to prevent calf diarrhea
Boehringer Ingelheim has launched Fencovis®, the first vaccine to prevent calf diarrhea caused by E. coli F5 and bovine rotavirus and reduce severity of...
TwistPak®: Mixing platform for swine vaccines brings convenience and flexibility
Boehringer Ingelheim unveiled its latest innovation: TwistPak®, a revolutionary mixing platform, which enables swine producers to combine two vaccines, Ingelvac CircoFLEX® and Ingelvac MycoFLEX®,...
PetPro products transition to Pawru branding
Boehringer Ingelheim Animal Health USA Inc. announced the creation of Pawru, Inc. as a separate Company within the Boehringer Ingelheim Animal Health business. The company's PetPro portfolio will transition to Pawru branding.
Boehringer Ingelheim is Global Top Employer 2021
The Top Employers Institute awarded Boehringer Ingelheim for the first time as a “Global Top Employer”.
Boehringer Ingelheim partners with PetMedix
Boehringer Ingelheim announced a multi-year partnership with PetMedix to develop novel and transformative companion animal antibody therapeutics using PetMedix’s proprietary Ky9 platform.
